PlasmaGen Biosciences, backed by Eight Road Ventures, raised Rs 150 crore led by ViNS Bioproducts. Funds will scale international operations, expand its product portfolio, and enhance manufacturing. The company focuses on plasma-derived therapies, aiming to address India’s critical medicine supply gap. Commercial operations began in 2024 at its Kolar facility.
Trending
- Acko Taps Top Banks for H1 2027 IPO Target
- Fairdeal.Market Secures US$15M to Scale B2B Quick Commerce Across India
- India’s Startup IPO Surge: 48+ Listings Set to Unlock INR 50,000 Cr in 2026
- Indian Startup IPO Surge Expected by 2026 Amid Market Reset
- IIT Madras Director Unfazed by India’s AI Sovereignty Concerns
- Flipkart Bolsters Leadership with Key VP Appointments
- IEA Warns Current Oil Crisis Exceeds Past Shocks
- HomeEssentials Secures $7.7M to Fuel Retail Expansion
PlasmaGen Biosciences Secures Rs 150 Crore to Expand Plasma-Derived Therapies
Deccan Founders © 2026 – All Rights Reserved